Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

“Project BioShield” Offers Funding Source For Biotech, McClellan Tells BIO

Executive Summary

The biotechnology industry should embrace Project BioShield as a guaranteed market for innovative counter-terrorism technologies, Commissioner McClellan said during the Biotechnology Industry Organization CEO and investor conference Feb. 27 in New York
Advertisement

Related Content

BIO Gets Pep Talk From Commander-In-Chief; Is Boom-And-Bust Cycle Over?
BIO Gets Pep Talk From Commander-In-Chief; Is Boom-And-Bust Cycle Over?
“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says
“Project BioShield” Model Could Apply More Broadly, FDA Commissioner Says
BioShield House Compromise Could Serve As Template For Senate
BioShield Markup In House Delayed As Administration Seeks Sustained Funding
Medicaid Reform Should Be PhRMA Priority, HHS Secretary Thompson Says
“Project BioShield”: Industry Has Concerns, FDA Offers Support
CBER “Best Practices” Must Be Preserved In Reorg, Mass Bio Tells McClellan
Commissioner McClellan Visits Mass Bio: Phase IV, Orphan Drugs On Agenda
Advertisement
UsernamePublicRestriction

Register

PS041364

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel